Pacific Biosciences of California (PACB): רווח נקי למניה (EPS TTM)

Pacific Biosciences revenues are based on the sale of Revio and Onso systems along with consumables. The rolling annual earnings per share reflect the sales dynamics of HiFi high-precision equipment for biopharmaceutical corporations. Within the long-read B2B ecosystem, a stable payment stream from laboratories is being established, while the value of -0.43 serves as the current indicator of the company's fundamental profit.

For Pacific Biosciences (PACB), which advances R&D through strategic alliances rather than costly acquisitions, this metric serves as a key measure of organic growth efficiency and the capitalization of internal innovations. By analyzing the 12-month net income per share snapshot on GURU.Markets, an investor can discern the business's actual unit profitability, stripped of the impact of share issuance, allowing for an objective assessment of the asset's fundamental value without market premiums.